publications-banner
Information about pipeline products
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
PublicationView
T-DXd
Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies
T-DXd
Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer.
Pexidartinib
Results from phase I extension study assessing pexidartinib treatment in six cohorts with solid tumors including TGCT, and abnormal CSF1 transcripts in TGCT
HER3-DXd
Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer
Edoxaban
One-year incidence of venous thromboembolism, bleeding, and death in patients with solid tumors newly initiating cancer treatment: Results from the Cancer-VTE registry
T-DXd
Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 study
Pexidartinib
Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: Results from the ENLIVEN randomized clinical trial